SEC Form 4 · accession 0001415889-16-007441
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kurt A Gustafson
Director
Period of report
Nov 14, 2016
Accepted (ET)
Nov 16, 2016 · 4:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386570
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Options (right to buy)F1 | $2.88 | Nov 14, 2016 | A | 40,000 | A | Nov 14, 2017 | Nov 14, 2026 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1Options vest 34% on November 14, 2017, 33% on November 14, 2018 and 33% on November 14, 2019.